Neurogene (NGNE) News Today $15.33 -0.81 (-5.02%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$15.06 -0.27 (-1.73%) As of 03/27/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period What is HC Wainwright's Forecast for Neurogene Q1 Earnings?Neurogene Inc. (NASDAQ:NGNE - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Neurogene in a research note issued on Tuesday, March 25th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.85) per shaMarch 28 at 6:00 AM | marketbeat.comQ1 Earnings Estimate for Neurogene Issued By Leerink PartnrsNeurogene Inc. (NASDAQ:NGNE - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Neurogene in a research note issued to investors on Monday, March 24th. Leerink Partnrs analyst M. Foroohar expects that the company will earn ($1.12) perMarch 28 at 6:00 AM | marketbeat.comWhat is William Blair's Estimate for Neurogene Q1 Earnings?Neurogene Inc. (NASDAQ:NGNE - Free Report) - Stock analysts at William Blair issued their Q1 2025 EPS estimates for shares of Neurogene in a research report issued on Tuesday, March 25th. William Blair analyst S. Corwin expects that the company will post earnings of ($0.92) per share for the quarMarch 28 at 6:00 AM | marketbeat.comStifel maintient sa recommandation d’achat sur Neurogene avec un objectif de 46$March 27 at 5:04 PM | fr.investing.comQ1 Earnings Estimate for Neurogene Issued By William BlairNeurogene Inc. (NASDAQ:NGNE - Free Report) - William Blair issued their Q1 2026 earnings estimates for Neurogene in a note issued to investors on Tuesday, March 25th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($1.18) per share for the quarter. William BlaiMarch 27 at 7:03 AM | marketbeat.comWilliam Blair Reaffirms Outperform Rating for Neurogene (NASDAQ:NGNE)March 27 at 3:19 AM | americanbankingnews.comNeurogene Reports 2024 Financial Results and Advances in Rett Syndrome TrialMarch 26 at 9:47 PM | tipranks.comWilliam Blair Reiterates "Outperform" Rating for Neurogene (NASDAQ:NGNE)William Blair reiterated an "outperform" rating on shares of Neurogene in a research report on Tuesday.March 26 at 12:26 PM | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Buy" by BrokeragesShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have earned a consensus rating of "Buy" from the eight brokerages that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1March 26 at 10:34 AM | marketbeat.comNeurogene price target lowered to $38 from $46 at BairdMarch 26 at 8:46 AM | markets.businessinsider.comNeurogene price target lowered to $50 from $55 at H.C. WainwrightMarch 26 at 8:46 AM | markets.businessinsider.comNeurogene (NASDAQ:NGNE) Price Target Cut to $50.00 by Analysts at HC WainwrightHC Wainwright dropped their price objective on shares of Neurogene from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday.March 26 at 8:34 AM | marketbeat.comNeurogene (NASDAQ:NGNE) Issues Quarterly Earnings ResultsNeurogene (NASDAQ:NGNE - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.05.March 26 at 8:09 AM | marketbeat.comNeurogene (NASDAQ:NGNE) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPSNeurogene (NASDAQ:NGNE - Get Free Report) announced its earnings results on Monday. The company reported ($0.99) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.05.March 26 at 7:50 AM | marketbeat.comHC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock PriceMarch 26 at 3:19 AM | americanbankingnews.comNeurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent UpdatesMarch 24, 2025 | businesswire.comChristine Mikail Cvijic Sells 4,501 Shares of Neurogene Inc. (NASDAQ:NGNE) StockNeurogene Inc. (NASDAQ:NGNE - Get Free Report) CFO Christine Mikail Cvijic sold 4,501 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the sale, the chief financial officer now owns 72,343 shares of the company's stock, valued at approximately $1,225,490.42. The trade was a 5.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.March 18, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) CFO Sells $76,246.94 in StockMarch 18, 2025 | insidertrades.comNeurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401March 7, 2025 | seekingalpha.comNeurogene Inc. (NASDAQ:NGNE) Short Interest UpdateNeurogene Inc. (NASDAQ:NGNE - Get Free Report) saw a large decline in short interest in February. As of February 15th, there was short interest totalling 1,750,000 shares, a decline of 12.9% from the January 31st total of 2,010,000 shares. Approximately 10.1% of the company's shares are short sold. Based on an average trading volume of 321,600 shares, the days-to-cover ratio is presently 5.4 days.March 7, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Shares Down 8.4% - Here's WhyNeurogene (NASDAQ:NGNE) Shares Down 8.4% - Here's What HappenedMarch 4, 2025 | marketbeat.comNeurogene Insiders Placed Bullish Bets Worth US$1.46mFebruary 15, 2025 | finance.yahoo.comNeurogene (NGNE) Projected to Post Quarterly Earnings on MondayNeurogene (NASDAQ:NGNE) will be releasing earnings before the market opens on Monday, February 17, Financial Modeling Prep reports.February 10, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEFebruary 4, 2025 | prnewswire.comNeurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Buy" from BrokeragesShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have earned an average rating of "Buy" from the eight analysts that are covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. ThJanuary 31, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEJanuary 28, 2025 | prnewswire.comNeurogene Inc. (NGNE)January 25, 2025 | ca.finance.yahoo.comLe titre NGNE atteint son plus bas niveau sur 52 semaines à 14,42$ face aux défis du marchéJanuary 24, 2025 | fr.investing.comNGNE Stock Hits 52-Week Low at $14.42 Amid Market ChallengesJanuary 24, 2025 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEJanuary 21, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEJanuary 8, 2025 | prnewswire.comNeurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Buy" by AnalystsNeurogene Inc. (NASDAQ:NGNE - Get Free Report) has been assigned an average rating of "Buy" from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. TJanuary 6, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEJanuary 2, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEDecember 27, 2024 | prnewswire.comState Street Corp Acquires 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE)State Street Corp lifted its stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) by 17.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 246,540 shares of the company's stock after acquiring an additional 36,687December 27, 2024 | marketbeat.comShort Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7%Neurogene Inc. (NASDAQ:NGNE - Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,170,000 shares, a decline of 28.7% from the November 15th total of 1,640,000 shares. Based on an average daily volume of 348,300 shares, the short-interest ratio is presently 3.4 days. Currently, 10.2% of the shares of the company are short sold.December 13, 2024 | marketbeat.comWilliam Blair Reaffirms Their Buy Rating on Neurogene (NGNE)December 13, 2024 | markets.businessinsider.comNeurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Buy" by AnalystsShares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strongDecember 12, 2024 | marketbeat.comFmr LLC Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE)Fmr LLC boosted its stake in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 912.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 731,801 shares of the company's stock after buying an additional 659,515 shares duDecember 9, 2024 | marketbeat.comJanus Henderson Group PLC Reduces Holdings in Neurogene Inc. (NASDAQ:NGNE)Janus Henderson Group PLC lowered its stake in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 15.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 709,469 shares of the company's stock after selling 125,322 shares during tDecember 7, 2024 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Shares Acquired by RTW Investments LPRTW Investments LP grew its stake in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 6.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,135,256 shares of the company's stock after purchasing an additionalDecember 5, 2024 | marketbeat.comRedmile Group LLC Sells 49,316 Shares of Neurogene Inc. (NASDAQ:NGNE)Redmile Group LLC reduced its position in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 4.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 964,347 shares of the company's stock after selling 49,316 sharesDecember 5, 2024 | marketbeat.comWalleye Capital LLC Reduces Stock Position in Neurogene Inc. (NASDAQ:NGNE)Walleye Capital LLC lessened its stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) by 51.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,500 shares of the company's stock afDecember 5, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNEDecember 3, 2024 | prnewswire.comNeurogene Inc. (NASDAQ:NGNE) Major Shareholder Acquires $1,259,729.10 in StockNovember 28, 2024 | insidertrades.comPositive Outlook on Neurogene’s NGN-401 Despite Setback: Buy Rating Reaffirmed with $55 Price TargetNovember 26, 2024 | markets.businessinsider.comNeurogene and Ventyx Biosciences rises after insider buying by executivesNovember 26, 2024 | msn.comNeurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic Acquires 24,000 SharesNovember 26, 2024 | insidertrades.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNENovember 25, 2024 | prnewswire.comHC Wainwright Reaffirms Buy Rating for Neurogene (NASDAQ:NGNE)HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of Neurogene in a research note on Monday.November 25, 2024 | marketbeat.com Remove Ads Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address NGNE Media Mentions By Week NGNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGNE News Sentiment▼0.740.78▲Average Medical News Sentiment NGNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGNE Articles This Week▼293▲NGNE Articles Average Week Remove Ads Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EOLS News AVDL News AVXL News PHVS News CDMO News QURE News ABCL News CMRX News PRAX News BCAX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NGNE) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
